◆ Latest: Retatrutide Phase 3 trial reports 24% weight reduction at 48 wks◆ Established: 10 peptides now FDA approved for metabolic indications◆ Preclinical: BPC-157 meta-analysis (17 rodent studies) published◆ Evidence: new mitochondrial peptide review covers MOTS-c, SS-31, Humanin◆ Safety: hCG supply disruption update, Q2 2026◆ Editorial: The Mitochondrial Decade, new long-read◆ Latest: Retatrutide Phase 3 trial reports 24% weight reduction at 48 wks◆ Established: 10 peptides now FDA approved for metabolic indications◆ Preclinical: BPC-157 meta-analysis (17 rodent studies) published◆ Evidence: new mitochondrial peptide review covers MOTS-c, SS-31, Humanin◆ Safety: hCG supply disruption update, Q2 2026◆ Editorial: The Mitochondrial Decade, new long-read

Definition

FDA Negative List

A list of bulk drug substances that the FDA has determined cannot be used for compounding under Section 503A. Several research peptides (including BPC-157) were added in 2023–2024.

Browse the full glossary

This site is for educational and research purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider before using any peptide or supplement.